Academic Journals Database
Disseminating quality controlled scientific knowledge

Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients

ADD TO MY LIST
 
Author(s): Jun Li | Han Zhang | Peng Sun | Feng Gu | Zhe-Li Liu

Journal: International Journal of Ophthalmology
ISSN 2222-3959

Volume: 6;
Issue: 2;
Start page: 169;
Date: 2013;
VIEW PDF   PDF DOWNLOAD PDF   Download PDF Original page

Keywords: age-related macular degeneration | choroidal neovascularization | bevacizumab (avastin) | ranibizumab (lucentis)

ABSTRACT
AIM:To compare the clinical efficacy of intravitreal injections of bevacizumab and ranibizumab for treating Chinese patients with neovascular age-related macular degeneration (AMD). METHODS: Among 60 Chinese patients with exudative AMD (60 eyes), 28 received intravitreal bevacizumab injections (1.25mg) and 32 received intravitreal ranibizumab injections (0.5mg), once a month for 3 months and were followed for a total of 6 months. Monthly optical coherence tomography (OCT) was used to determine whether the patients received additional treatments during the follow-up. We compared the baseline and 6-month follow-up values of mean best-corrected visual acuity (BCVA) and central retinal thickness (CRT) in both groups of patients. We also compared the occurrence of adverse events. RESULTS:At the 6-month follow-up, the mean BCVA (logMAR) of the bevacizumab and ranibizumab treatment groups improved from the baseline measurements of 0.72±0.23 and 0.73±0.22 to 0.47±0.14 and 0.45±0.20, respectively (P
Affiliate Program      Why do you need a reservation system?